Polysorbate 20 increases oral absorption of digoxin in wild-type Sprague Dawley rats, but not in mdr1a(-/-) Sprague Dawley rats
Graphical abstract
Introduction
ATP-binding cassette (ABC) transporters affect drug absorption, distribution, metabolism, excretion and toxicity (ADMET) properties (Akazawa et al., 2016, Szakacs et al., 2008). The interaction of drugs with ABC-transporters, such as P-glycoprotein (P-gp, MDR1, ABCB1) or breast-cancer resistance protein (BCRP), limits the transport across the intestinal barrier and the blood brain barrier (Glavinas et al., 2004). Furthermore, in cases with polypharmacy were more than one of the administered drugs are substrates for ABC transporters cellular drug concentrations in the kidney and liver are affected (Funk, 2008), which may lead to clinically relevant drug–drug interactions. In the case of intestinal transport, the interaction between a drug substance and P-gp limits transepithelial absorptive permeation, thus limiting the oral bioavailability. This is especially relevant for drug substances with low solubility and high affinity for P-gp (Montanari and Ecker, 2015). In the intestine the expression of P-gp mRNA is increased from the duodenum to the colon in mouse (Mutch et al., 2004), rat (Takara et al., 2003) and human (Zimmermann et al., 2005). At the protein level, P-gp is expressed in the luminal membrane of e.g. Caco-2 cells (Hunter et al., 1993), and the absolute P-gp protein level has also been shown to increase from duodenum to ileum in mouse (Akazawa et al., 2016), and human (Bruyere et al., 2010, Mouly and Paine, 2003). P-gp substrate are likely recognized by the transporter in the inner leaflet of the membrane and either moved to the outer leaflet or the extracellular space using ATP to complete the transport (Sharom, 2014).
Strategies to improve solubility of drug substances and inhibit ABC-transporter mediated cellular efflux in order to increase oral bioavailability are in high demand in drug formulation programs. Several non-ionic surfactants such as polysorbates (tween) and poloxamers have been investigated for their ability to increase in vitro absorption by inhibiting efflux transporters (Bogman et al., 2003, Cornaire et al., 2000, Nerurkar et al., 1996, Nerurkar et al., 1997, Rege et al., 2001, Shono et al., 2004, Takahashi et al., 2002, Wang et al., 2004). This approach originates from findings in cancer cell lines (Woodcock et al., 1992), where Woodcock and co-workers showed that detergents with polyethylene oxide hydrophilic moieties, like cremophor EL, tween 20 and 80, were able to reverse the MDR phenotype in cancer cells in a reversible manner (Woodcock et al., 1992). Despite the many in vitro studies, only few studies have explored the ability of surfactants to increase bioavailability in in vivo models. Furthermore, systematic and mechanistic studies investigating the amount of surfactant needed in vivo to increase absorption are to the best of our knowledge lacking. To distinguish between solubility and transport-mediated effects knock-out animals may provide a powerful tool. To this end, it has been shown that polysorbate 20 and pluronic P85 increase the absorption of topotecan, a BCRP substrate, in wild type mice, without affecting absorption in bcrp (-/-) mice (Yamagata et al., 2007).
We recently showed that even though polysorbate 20 and 80 increased the absorptive doxorubicin transport across Caco-2 cells, this did not translate into a measurable increase in plasma concentrations in vivo after oral administration of doxorubicin and 1–25% (w/v) polysorbate 20 to rats, likely due to hepatic clearance of doxorubicin (Al-Saraf et al., 2016). In contrast, polysorbate 80 has been shown to increase digoxin exposure evaluated as area under the plasma concentration time profile (AUC) and the maximal plasma concentration (Cmax) at concentrations of 1 and 10% in rats (Zhang et al., 2003). For further development of drug formulations containing surfactants specifically included to alter efflux transporter function more knowledge about the effect in vivo and knowledge of translation of in vitro to in vivo concentrations are needed. In the present study we have therefore investigated the in vitro and in vivo concentration dependent ability of polysorbate 20 to increase absorption of a low-soluble P-pg marker, i.e.digoxin. Digoxin was chosen as a p-gp marker since it is a low-permeable drug substance, which is a relatively specific substrate for p-gp as compared to BCRP and MRP2. The aim of the present study was thus to investigate the ability of polysorbate 20 to increase digoxin absorption in vitro by inhibiting P-gp mediated cellular efflux, and to investigate the dose of polysorbate 20 required to alter in vivo absorption of digoxin in wild type Sprague Dawley rats, and to use mdr1a (-/-) Sprague Dawley rats to distinguish between transporter and solubility related event during absorption.
Section snippets
Materials
Caco-2 cells were obtained from DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen) (Braunschweig, Germany) and MDCKII-MDR1 cells were obtained from the Netherlands Cancer Institute (Amsterdam, the Netherlands). Cell culture plastic ware was obtained from Corning Life Sciences (Tewksbury, MA, USA). All chemicals were from Sigma Aldrich (Broendby, Denmark), unless otherwise stated. Hanks Balanced Salt Solution (HBSS) buffer was from Invitrogen (Naerum, Denmark). Polysorbate 20 and
Polysorbates increase the absorptive transport of digoxin across Caco-2 cell monolayers
In an initial series of experiments the transport of digoxin across filter-grown Caco-2 cell monolayers was investigated as a function of time in the absence or presence of 100 μM quinidine or 200 μM polysorbate 20, 40, 60 or 80 (Fig. 1). Quinidine was present in both the donor and acceptor chamber, while polysorbates were only present in the buffer solutions applied to the apical chamber. It was evident that the transport of digoxin in absence of quinidine or polysorbate was strongly polarized
Discussion
We have investigated the ability of different polysorbates to increase the intestinal absorption of digoxin in vitro by using Caco-2 cells. Polysorbate 20 was selected for further studies, and the amount of polysorbate 20 required to increase digoxin absorption in vitro in MDCKII-MDR1 and Caco-2 cells as well as in vivo in wild type Sprague Dawley rats was investigated. To investigate the specificity of the underlying mechanism for the increased absorption of digoxin in the presence of
Conclusion
In conclusion, polysorbate 20 increased the absorptive transport of the low-soluble P-gp substrate, digoxin, across MDCKII-MDR1 and Caco-2 cell monolayers. The concentration required to increase absorptive transport is higher than the one required to decrease secretory transport. The amount of polysorbate 20 required to increase the oral bioavailability of digoxin in vivo was 10% of the dosing volume. Since polysorbate 20 did not increase digoxin absorption in Sprague Dawley mdr1a(-/-) rats,
Declaration of interest
The authors do not have any conflict of interest to report.
Author contribution
Conception and design of the study: CUN, AAA, DC and RH. Acquisition of data: AAA and DC. Analysis and interpretation of data: CUN, AAA, DC and RH. Drafting the article: CUN. Critical revising and final approval of the version submitted: CUN, AAA, DC and RH.
Acknowledgements
The cell culture facility at Department of Pharmacy, University of Copenhagen and Department of Physics, Chemistry and Pharmacy, University of Southern Denmark is acknowledged for cell culturing (Maria Pedersen) and the staff at the animal facility at H. Lundbeck A/S for help with performing the animal study. Parts of the experimental work were performed during Carsten Uhd Nielseńs employment at University of Copenhagen. Bachelor Thesis students Farhan Hassan Ali, Mohammed El Khatib, Nasrin
References (53)
- et al.
Tween 20 increases intestinal transport of doxorubicin in vitro but not in vivo
Int. J. Pharm.
(2016) - et al.
The role of surfactants in the reversal of active transport mediated by multidrug resistance proteins
J. Pharm. Sci.
(2003) - et al.
Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein
J. Biol. Chem.
(1987) - et al.
Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells: kinetics of vinblastine secretion and interaction with modulators
J. Biol. Chem.
(1993) - et al.
Impact of cremophor-EL and polysorbate-80 on digoxin permeability across rat jejunum: delineation of thermodynamic and transporter related events using the reciprocal permeability approach
J. Pharm. Sci.
(2007) - et al.
Exploring the P-glycoprotein binding cavity with polyoxyethylene alkyl ethers
Biophys. J.
(2010) Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines
J. Control. Release
(2003)- et al.
Prediction of drug-ABC-transporter interaction–recent advances and future challenges
Adv. Drug Deliv. Rev.
(2015) - et al.
Mechanistic roles of neutral surfactants on concurrent polarized and passive membrane transport of a model peptide in Caco-2 cells
J. Pharm. Sci.
(1997) - et al.
Nutritional studies on rats on diets containing high levels of partial ester emulsifiers. IV. Mortality and post-mortem pathology; general conclusions
J. Nutr.
(1957)
Effect of common excipients on Caco-2 transport of low-permeability drugs
J. Pharm. Sci.
Prodrug approach to improve absorption of prednisolone
Int. J. Pharm.
Modulation of intestinal P-glycoprotein function by cremophor EL and other surfactants by an in vitro diffusion chamber method using the isolated rat intestinal membranes
J. Pharm. Sci.
The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox)
Drug Discov. Today
Common solubilizers to estimate the Caco-2 transport of poorly water-soluble drugs
Int. J. Pharm.
Evaluation of cytotoxicity of surfactants used in self-micro emulsifying drug delivery systems and their effects on paracellular transport in Caco-2 cell monolayer
Eur. J. Pharm. Sci.
Determination of P-glycoprotein inhibition by excipients and their combinations using an integrated high-throughput process
J. Pharm. Sci.
The effect of cell culture conditions on saquinavir transport through, and interactions with, MDCKII cells overexpressing hMDR1
J. Pharm. Sci.
The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin
Biochem. Biophys. Res. Commun.
Quantitative targeted absolute proteomics of transporters and pharmacoproteomics-based reconstruction of P-Glycoprotein function in mouse small intestine
Mol. Pharm.
Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass
Mol. Pharm.
Rapid identification of P-glycoprotein substrates and inhibitors
Drug Metab. Dispos.
Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome
Nature
Effect of polyoxyl 35 castor oil and Polysorbate 80 on the intestinal absorption of digoxin in vitro
Arzneimittelforschung
Intermediary metabolism of certain polyoxyethylene derivatives in man. I. Recovery of the polyoxyethylene moiety from urine and faces following ingestion of polyoxyethylene (40) mono-stearate
J. Pharmacol. Exp. Ther.
Fabrication of two-layered channel system with embedded electrodes to measure resistance across epithelial and endothelial barriers
Anal. Chem.
Cited by (19)
P-glycoprotein-mediated transport in a mucus-supplemented Caco-2 cell model in the presence of different surfactants
2022, International Journal of PharmaceuticsHigh-dose etoposide formulations do not saturate intestinal P-glycoprotein: Development, stability, and pharmacokinetics in Sprague-Dawley rats
2020, International Journal of PharmaceuticsCitation Excerpt :In vivo, in wild type (WT) rats, P-gp restricts the oral bioavailability of several P-gp substrates such as loperamide (Zamek-Gliszczynski et al., 2012), paclitaxel (Zamek-Gliszczynski et al., 2012), digoxin (Nielsen et al., 2016), and etoposide (Al-Ali et al., 2018a). This is evident since the oral bioavailability is significantly increased in mdr1a deficient rats (Al-Ali et al., 2018a; Nielsen et al., 2016; Zamek-Gliszczynski et al., 2012). Moreover, co-administration of P-gp substrates with potent small-molecular P-gp inhibitors such as verapamil (Tsuruo et al., 1981), dexverapamil (Gramatté and Oertel, 1999), valspodar (PSC-833) (Mayer et al., 1997; vanAsperen et al., 1997), or zosuquidar (LY335979) (Bardelmeijer et al., 2004) increased the oral bioavailability of the substrates in preclinical studies.
Montmorillonite-surfactant hybrid particles for modulating intestinal P-glycoprotein-mediated transport
2019, International Journal of PharmaceuticsSimultaneous induction of biomass and lipid production in Tetradesmus obliquus BPL16 through polysorbate supplementation
2019, Renewable EnergyCitation Excerpt :Polysorbates had certain significant functional vitalities which are essentially exploited in various disciplines. For instance, Polysorbate 20 enhanced the absorptive transport across cell monolayers and invivo in mice [17]. There are numerous reports dealt with successful application of polysorbates as drug carriers especially micro emulsion based drug delivery formulations.
Nonionic surfactants modulate the transport activity of ATP-binding cassette (ABC) transporters and solute carriers (SLC): Relevance to oral drug absorption
2019, International Journal of PharmaceuticsMRP2-mediated transport of etoposide in MDCKII MRP2 cells is unaffected by commonly used non-ionic surfactants
2019, International Journal of Pharmaceutics
- 1
Present address: Drug Product Development, Janssen R&D, Johnson & Johnson, Turnhoutseweg 30, 2340 Beerse, Belgium